Cyclo Therapeutics inks $3M convertible note with Rafael Holdings

Published 2025-01-03, 04:04 p/m
CYTH
-

Cyclo Therapeutics, Inc. (NASDAQ:CYTH), a biopharmaceutical company, announced today that it has entered into a Seventh Amended and Restated Note Purchase Agreement with Rafael Holdings, Inc., issuing a convertible promissory note worth $3 million. The note, due on February 15, 2025, carries an interest rate of 5% per annum, payable upon maturity.

The newly issued note is part of a series of financing agreements between Cyclo Therapeutics and Rafael Holdings, dating back to an initial convertible promissory note issued on June 11, 2024. The series of agreements have provided Cyclo Therapeutics with a steady stream of capital, with the latest note amendable to prior agreements ranging from June to December 2024.

Under the terms of the note, Rafael Holdings has the option to convert the principal amount into shares of Cyclo Therapeutics' common stock prior to repayment. The conversion could occur automatically in the event of a Qualified Financing, at Rafael's discretion upon a Sale Transaction (JO:TCPJ), or if a Merger Agreement dated August 21, 2024, and amended on December 18, 2024, is executed. This Merger Agreement outlines a potential merger between Cyclo Therapeutics and a wholly-owned subsidiary of Rafael Holdings.

The note may be prepaid in full at any time by Cyclo Therapeutics. However, if an Event of Default occurs, including failure to pay the principal or interest when due, the obligations may be accelerated.

Cyclo Therapeutics intends to use the proceeds from the note for working capital and general corporate purposes. This financing strategy aligns with the company's ongoing efforts to support its operations and development programs.

Rafael Holdings currently holds approximately 39.5% of Cyclo Therapeutics' common stock, making it a significant shareholder with substantial interest in the company's success.

The news above is based on an SEC filing.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.